drugset

drugset / Trial / NCT04265755

Biomarker and Genetic Predictors of Erenumab Treatment Response

NCT04265755 ↗

Phase 4 Completed 1406 enrolled Amgen

NaSingle-groupOpen-labelTreatment

Summary

To explore the relationship between clinical response to erenumab and genetic biomarkers

Timeline

Start: 2020-10-26
Primary completion: 2023-01-18
Completion: 2023-01-18

Publications

Thuraiaiyah J, Ashina H, Christensen RH, Al-Khazali HM, Wiggers A, Amin FM, Steiner TJ, Ashina M. Premonitory symptoms in migraine: A REFORM Study. Cephalalgia. 2024 Feb;44(2):3331024231223979. doi: 10.1177/03331024231223979.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erenumab	Monoclonal antibody	70 mg	—
Subject	Erenumab	Monoclonal antibody	140 mg	—

Indications